Clinical Trials · NCT00927186

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

CompletedPhase 4Teriparatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
69
Start date
Jul 2009
Locations
12 sites, United States, Canada
Primary endpoint
Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months
View Teriparatide compound reference